Olmesartan-based versus Amlodipine-based Strategies for Circulating Marker Modification in Essential Hypertension Study
Not Applicable
- Conditions
- Essential Hypertension
- Registration Number
- JPRN-UMIN000000525
- Lead Sponsor
- Department of Cardiovascular Medicine, Kyoto University Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 400
Inclusion Criteria
Not provided
Exclusion Criteria
1.Cerebrovascular and cardiovascular events including myocardial infarction, cerebral infarction, cerebral hemorrahge and subarchnoidal hemorrahge within 6 months. 2.PTCA or CABG performed within 6 months. 3.Scheduled PTCA or CABG in the future. 4.Congenital or rheumatic heart disease. 5.Severe arrhythmia. 6.Severe liver insufficiency. 7.Severe renal insufficiency. 8.Active cancer or treatment for cancer within 5 years. 9.Pregnancy, possible pregnancy. 10.Not suitable to the clinical trial as judged by a physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method (1) Cardiovascular risk marker levels (2) Changes in cardiovascular risk marker levels
- Secondary Outcome Measures
Name Time Method Major cardiovascular adverse events (cardiac death, non-fatal myocardial infarction, revascularization or hospitalization by angina, hospitalization by heart failure, cerebrovascular events: cerebral infarction, cerebral hemorrhage, subarchnoidal hemorrhage)